Boston Trust Walden Corp Has $18.51 Million Stake in Amphastar Pharmaceuticals, Inc. $AMPH

Boston Trust Walden Corp lowered its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 13.1% in the first quarter, Holdings Channel reports. The firm owned 944,789 shares of the company’s stock after selling 142,477 shares during the quarter. Boston Trust Walden Corp’s holdings in Amphastar Pharmaceuticals were worth $18,508,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMPH. Clark Capital Management Group Inc. bought a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at about $7,560,000. SG Americas Securities LLC bought a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $2,504,000. Denali Advisors LLC grew its stake in Amphastar Pharmaceuticals by 56.9% in the fourth quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock valued at $5,671,000 after purchasing an additional 76,765 shares in the last quarter. Algert Global LLC increased its position in shares of Amphastar Pharmaceuticals by 216.1% during the 3rd quarter. Algert Global LLC now owns 392,902 shares of the company’s stock worth $10,471,000 after purchasing an additional 268,612 shares during the last quarter. Finally, Bridge City Capital LLC increased its position in shares of Amphastar Pharmaceuticals by 72.8% during the 4th quarter. Bridge City Capital LLC now owns 235,485 shares of the company’s stock worth $6,306,000 after purchasing an additional 99,227 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $19.64 on Friday. The stock has a market cap of $865.93 million, a P/E ratio of 11.83, a price-to-earnings-growth ratio of 3.86 and a beta of 0.89. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The stock has a 50 day simple moving average of $19.70 and a 200 day simple moving average of $22.67.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million for the quarter, compared to the consensus estimate of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. On average, research analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on AMPH. Weiss Ratings downgraded Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, June 22nd. Barclays dropped their target price on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Five analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $22.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.